BG108286A - Използване на азитромицин за получаване на фармацевтично средство за лечение на възпалителни неинфекциозни заболявания - Google Patents

Използване на азитромицин за получаване на фармацевтично средство за лечение на възпалителни неинфекциозни заболявания Download PDF

Info

Publication number: BG108286A
Authority: BG; Bulgaria
Prior art keywords: substituted; unsubstituted; alkyl; group; independently
Prior art date: 2001-04-27

Application number

BG108286A

Other languages

Bulgarian (bg)

English (en)

Inventor

Ognjen Culic

Michael Parnham

Vesna Erakovic

Original Assignee

Pliva D.D.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-04-27

Filing date

2003-10-23

Publication date

2004-09-30

2003-10-23 Application filed by Pliva D.D. filed Critical Pliva D.D.

2004-09-30 Publication of BG108286A publication Critical patent/BG108286A/bg

Links

238000004519 manufacturing process Methods 0.000 title abstract description 12
208000027866 inflammatory disease Diseases 0.000 title abstract description 3
MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 title abstract 3
229960004099 azithromycin Drugs 0.000 title abstract 3
230000001524 infective effect Effects 0.000 title abstract 2
238000011282 treatment Methods 0.000 title description 21
239000003814 drug Substances 0.000 title description 18
-1 imidazo [1,2-a] pyrimidinyl Chemical group 0.000 claims description 340
150000001875 compounds Chemical class 0.000 claims description 329
125000000217 alkyl group Chemical group 0.000 claims description 224
125000003118 aryl group Chemical group 0.000 claims description 125
125000000623 heterocyclic group Chemical group 0.000 claims description 100
239000000203 mixture Substances 0.000 claims description 90
229910052739 hydrogen Inorganic materials 0.000 claims description 85
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 80
239000001257 hydrogen Substances 0.000 claims description 79
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 75
229910052757 nitrogen Inorganic materials 0.000 claims description 73
125000001424 substituent group Chemical group 0.000 claims description 70
125000003710 aryl alkyl group Chemical group 0.000 claims description 61
125000004433 nitrogen atom Chemical group N* 0.000 claims description 55
125000001072 heteroaryl group Chemical group 0.000 claims description 53
125000003545 alkoxy group Chemical group 0.000 claims description 46
125000000753 cycloalkyl group Chemical group 0.000 claims description 45
229910005965 SO 2 Inorganic materials 0.000 claims description 38
150000003839 salts Chemical class 0.000 claims description 36
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 35
229910052717 sulfur Inorganic materials 0.000 claims description 35
229910004013 NO 2 Inorganic materials 0.000 claims description 32
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 32
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 28
125000004093 cyano group Chemical group *C#N 0.000 claims description 28
229910052736 halogen Inorganic materials 0.000 claims description 28
150000002367 halogens Chemical class 0.000 claims description 28
229920006395 saturated elastomer Polymers 0.000 claims description 28
125000000592 heterocycloalkyl group Chemical group 0.000 claims description 27
125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 26
229910052760 oxygen Inorganic materials 0.000 claims description 25
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 23
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 23
125000002541 furyl group Chemical group 0.000 claims description 20
125000004446 heteroarylalkyl group Chemical group 0.000 claims description 20
125000000719 pyrrolidinyl group Chemical group 0.000 claims description 20
125000004076 pyridyl group Chemical group 0.000 claims description 19
125000000392 cycloalkenyl group Chemical group 0.000 claims description 18
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 18
239000002207 metabolite Substances 0.000 claims description 18
125000001544 thienyl group Chemical group 0.000 claims description 18
239000000651 prodrug Substances 0.000 claims description 17
229940002612 prodrug Drugs 0.000 claims description 17
125000000168 pyrrolyl group Chemical group 0.000 claims description 17
125000004183 alkoxy alkyl group Chemical group 0.000 claims description 16
125000005518 carboxamido group Chemical group 0.000 claims description 16
125000002883 imidazolyl group Chemical group 0.000 claims description 16
125000002971 oxazolyl group Chemical group 0.000 claims description 16
125000003386 piperidinyl group Chemical group 0.000 claims description 16
125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 15
125000003226 pyrazolyl group Chemical group 0.000 claims description 15
125000004103 aminoalkyl group Chemical group 0.000 claims description 14
125000005843 halogen group Chemical group 0.000 claims description 14
229910052698 phosphorus Inorganic materials 0.000 claims description 14
125000003368 amide group Chemical group 0.000 claims description 13
125000000547 substituted alkyl group Chemical group 0.000 claims description 13
125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 13
125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 12
125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 12
125000005842 heteroatom Chemical group 0.000 claims description 12
125000001041 indolyl group Chemical group 0.000 claims description 12
125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 12
125000003831 tetrazolyl group Chemical group 0.000 claims description 12
125000004448 alkyl carbonyl group Chemical group 0.000 claims description 11
125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 11
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 11
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 11
125000002102 aryl alkyloxo group Chemical group 0.000 claims description 10
125000005110 aryl thio group Chemical group 0.000 claims description 10
125000001589 carboacyl group Chemical group 0.000 claims description 10
125000005114 heteroarylalkoxy group Chemical group 0.000 claims description 10
125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 10
125000000842 isoxazolyl group Chemical group 0.000 claims description 10
125000001624 naphthyl group Chemical group 0.000 claims description 10
230000003287 optical effect Effects 0.000 claims description 10
125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 10
125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 10
125000005368 heteroarylthio group Chemical group 0.000 claims description 9
125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 claims description 9
125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims description 9
125000000335 thiazolyl group Chemical group 0.000 claims description 9
125000003342 alkenyl group Chemical group 0.000 claims description 8
125000000304 alkynyl group Chemical group 0.000 claims description 8
125000004104 aryloxy group Chemical group 0.000 claims description 8
125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 8
125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 claims description 8
125000005553 heteroaryloxy group Chemical group 0.000 claims description 8
125000000714 pyrimidinyl group Chemical group 0.000 claims description 8
125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 claims description 8
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 7
125000002837 carbocyclic group Chemical group 0.000 claims description 7
125000004437 phosphorous atom Chemical group 0.000 claims description 7
239000011574 phosphorus Substances 0.000 claims description 7
125000003373 pyrazinyl group Chemical group 0.000 claims description 7
125000002098 pyridazinyl group Chemical group 0.000 claims description 7
125000003806 alkyl carbonyl amino group Chemical group 0.000 claims description 6
125000006356 alkylene carbonyl group Chemical group 0.000 claims description 6
125000002947 alkylene group Chemical group 0.000 claims description 6
125000004658 aryl carbonyl amino group Chemical group 0.000 claims description 6
125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 6
125000001786 isothiazolyl group Chemical group 0.000 claims description 6
125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims description 6
125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 6
125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 5
125000003277 amino group Chemical group 0.000 claims description 5
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 5
125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 5
125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 4
125000001715 oxadiazolyl group Chemical group 0.000 claims description 4
125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 claims description 4
125000001113 thiadiazolyl group Chemical group 0.000 claims description 4
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 3
125000005129 aryl carbonyl group Chemical group 0.000 claims description 3
125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims description 3
125000005958 tetrahydrothienyl group Chemical group 0.000 claims description 3
125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 claims description 2
WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 2
DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 claims description 2
125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 2
125000005224 heteroarylcarbonylamino group Chemical group 0.000 claims description 2
125000002757 morpholinyl group Chemical group 0.000 claims description 2
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
150000002431 hydrogen Chemical group 0.000 claims 21
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 3
125000005223 heteroarylcarbonyl group Chemical group 0.000 claims 3
125000004391 aryl sulfonyl group Chemical group 0.000 claims 2
229910052799 carbon Inorganic materials 0.000 claims 2
HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims 2
ACTKAGSPIFDCMF-UHFFFAOYSA-N 1,3-oxazol-2-amine Chemical compound NC1=NC=CO1 ACTKAGSPIFDCMF-UHFFFAOYSA-N 0.000 claims 1
CWLUFVAFWWNXJZ-UHFFFAOYSA-N 1-hydroxypyrrolidine Chemical compound ON1CCCC1 CWLUFVAFWWNXJZ-UHFFFAOYSA-N 0.000 claims 1
WKMSPQCXGSSZRL-UHFFFAOYSA-N 2,6-dihydro-1-benzofuran Chemical compound C1C=CC2=CCOC2=C1 WKMSPQCXGSSZRL-UHFFFAOYSA-N 0.000 claims 1
CNPURSDMOWDNOQ-UHFFFAOYSA-N 4-methoxy-7h-pyrrolo[2,3-d]pyrimidin-2-amine Chemical compound COC1=NC(N)=NC2=C1C=CN2 CNPURSDMOWDNOQ-UHFFFAOYSA-N 0.000 claims 1
SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 claims 1
125000005143 heteroarylsulfonyl group Chemical group 0.000 claims 1
125000004193 piperazinyl group Chemical group 0.000 claims 1
238000000034 method Methods 0.000 abstract description 68
239000008194 pharmaceutical composition Substances 0.000 abstract description 12
238000007911 parenteral administration Methods 0.000 abstract description 3
238000002560 therapeutic procedure Methods 0.000 abstract description 2
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 165
210000004027 cell Anatomy 0.000 description 73
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 65
230000000694 effects Effects 0.000 description 63
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 57
239000011541 reaction mixture Substances 0.000 description 56
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 55
239000005695 Ammonium acetate Substances 0.000 description 55
235000019257 ammonium acetate Nutrition 0.000 description 55
229940043376 ammonium acetate Drugs 0.000 description 55
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 51
239000007787 solid Substances 0.000 description 48
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 42
201000010099 disease Diseases 0.000 description 40
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 39
102000001253 Protein Kinase Human genes 0.000 description 39
108060006633 protein kinase Proteins 0.000 description 38
206010028980 Neoplasm Diseases 0.000 description 37
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 37
QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 37
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 36
239000012321 sodium triacetoxyborohydride Substances 0.000 description 36
239000000243 solution Substances 0.000 description 36
QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 34
108091000080 Phosphotransferase Proteins 0.000 description 33
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 33
102000020233 phosphotransferase Human genes 0.000 description 33
102000005962 receptors Human genes 0.000 description 33
108020003175 receptors Proteins 0.000 description 33
235000002639 sodium chloride Nutrition 0.000 description 33
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 29
101100481410 Mus musculus Tek gene Proteins 0.000 description 29
101100481408 Danio rerio tie2 gene Proteins 0.000 description 27
239000003446 ligand Substances 0.000 description 27
KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 26
238000006243 chemical reaction Methods 0.000 description 26
230000005764 inhibitory process Effects 0.000 description 26
239000002244 precipitate Substances 0.000 description 26
206010030113 Oedema Diseases 0.000 description 25
108090000623 proteins and genes Proteins 0.000 description 24
101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 23
101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 23
108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 23
201000011510 cancer Diseases 0.000 description 23
238000001914 filtration Methods 0.000 description 23
102000004190 Enzymes Human genes 0.000 description 22
108090000790 Enzymes Proteins 0.000 description 22
208000035475 disorder Diseases 0.000 description 22
229940088598 enzyme Drugs 0.000 description 22
230000033115 angiogenesis Effects 0.000 description 21
230000002401 inhibitory effect Effects 0.000 description 21
SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 20
102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 20
241000282414 Homo sapiens Species 0.000 description 19
108010034265 Vascular Endothelial Growth Factor Receptors Proteins 0.000 description 19
239000003112 inhibitor Substances 0.000 description 19
235000018102 proteins Nutrition 0.000 description 19
102000004169 proteins and genes Human genes 0.000 description 19
108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 18
230000001404 mediated effect Effects 0.000 description 18
102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 17
238000001994 activation Methods 0.000 description 17
238000002360 preparation method Methods 0.000 description 17
102000027426 receptor tyrosine kinases Human genes 0.000 description 17
108091008598 receptor tyrosine kinases Proteins 0.000 description 17
239000000758 substrate Substances 0.000 description 17
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
241000699670 Mus sp. Species 0.000 description 16
230000004913 activation Effects 0.000 description 16
230000015572 biosynthetic process Effects 0.000 description 16
239000000872 buffer Substances 0.000 description 16
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
229910052731 fluorine Inorganic materials 0.000 description 15
238000005755 formation reaction Methods 0.000 description 15
229910052740 iodine Inorganic materials 0.000 description 15
230000004044 response Effects 0.000 description 15
102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 14
230000002491 angiogenic effect Effects 0.000 description 14
239000002552 dosage form Substances 0.000 description 14
XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 13
210000001744 T-lymphocyte Anatomy 0.000 description 13
102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 13
150000001413 amino acids Chemical group 0.000 description 13
210000002889 endothelial cell Anatomy 0.000 description 13
230000008728 vascular permeability Effects 0.000 description 13
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
108091007914 CDKs Proteins 0.000 description 12
238000002965 ELISA Methods 0.000 description 12
241001465754 Metazoa Species 0.000 description 12
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 12
206010029113 Neovascularisation Diseases 0.000 description 12
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 12
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 12
230000014509 gene expression Effects 0.000 description 12
239000003102 growth factor Substances 0.000 description 12
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 12
238000006366 phosphorylation reaction Methods 0.000 description 12
230000008569 process Effects 0.000 description 12
FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 12
230000002792 vascular Effects 0.000 description 12
229960000583 acetic acid Drugs 0.000 description 11
125000004453 alkoxycarbonyl group Chemical group 0.000 description 11
229940024606 amino acid Drugs 0.000 description 11
230000004663 cell proliferation Effects 0.000 description 11
238000001727 in vivo Methods 0.000 description 11
230000035699 permeability Effects 0.000 description 11
239000003826 tablet Substances 0.000 description 11
108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 description 10
235000001014 amino acid Nutrition 0.000 description 10
239000002585 base Substances 0.000 description 10
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 10
230000001413 cellular effect Effects 0.000 description 10
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 10
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 10
125000002768 hydroxyalkyl group Chemical group 0.000 description 10
239000002953 phosphate buffered saline Substances 0.000 description 10
230000026731 phosphorylation Effects 0.000 description 10
230000035755 proliferation Effects 0.000 description 10
230000000638 stimulation Effects 0.000 description 10
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 10
125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 9
101150012716 CDK1 gene Proteins 0.000 description 9
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 9
108090000315 Protein Kinase C Proteins 0.000 description 9
102000003923 Protein Kinase C Human genes 0.000 description 9
102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 9
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
208000025865 Ulcer Diseases 0.000 description 9
102100038232 Vascular endothelial growth factor C Human genes 0.000 description 9
230000033228 biological regulation Effects 0.000 description 9
239000002775 capsule Substances 0.000 description 9
229910052801 chlorine Inorganic materials 0.000 description 9
230000006870 function Effects 0.000 description 9
239000007924 injection Substances 0.000 description 9
238000002347 injection Methods 0.000 description 9
230000003834 intracellular effect Effects 0.000 description 9
210000001519 tissue Anatomy 0.000 description 9
231100000397 ulcer Toxicity 0.000 description 9
102100040681 Platelet-derived growth factor C Human genes 0.000 description 8
201000004681 Psoriasis Diseases 0.000 description 8
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 description 8
239000002253 acid Substances 0.000 description 8
239000004480 active ingredient Substances 0.000 description 8
239000003795 chemical substances by application Substances 0.000 description 8
229940079593 drug Drugs 0.000 description 8
208000015181 infectious disease Diseases 0.000 description 8
239000002609 medium Substances 0.000 description 8
125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 8
108010017992 platelet-derived growth factor C Proteins 0.000 description 8
230000019491 signal transduction Effects 0.000 description 8
230000001225 therapeutic effect Effects 0.000 description 8
241000701447 unidentified baculovirus Species 0.000 description 8
239000003981 vehicle Substances 0.000 description 8
108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 7
102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 7
102000003903 Cyclin-dependent kinases Human genes 0.000 description 7
108090000266 Cyclin-dependent kinases Proteins 0.000 description 7
101100059559 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) nimX gene Proteins 0.000 description 7
206010016654 Fibrosis Diseases 0.000 description 7
210000004204 blood vessel Anatomy 0.000 description 7
229910052794 bromium Inorganic materials 0.000 description 7
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 7
230000003463 hyperproliferative effect Effects 0.000 description 7
208000028867 ischemia Diseases 0.000 description 7
239000002773 nucleotide Substances 0.000 description 7
125000003729 nucleotide group Chemical group 0.000 description 7
125000004430 oxygen atom Chemical group O* 0.000 description 7
239000000546 pharmaceutical excipient Substances 0.000 description 7
229920000728 polyester Polymers 0.000 description 7
239000001267 polyvinylpyrrolidone Substances 0.000 description 7
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 7
230000004936 stimulating effect Effects 0.000 description 7
239000000126 substance Substances 0.000 description 7
239000000725 suspension Substances 0.000 description 7
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 7
229940121358 tyrosine kinase inhibitor Drugs 0.000 description 7
210000004291 uterus Anatomy 0.000 description 7
210000003556 vascular endothelial cell Anatomy 0.000 description 7
108091003079 Bovine Serum Albumin Proteins 0.000 description 6
101100464293 Caenorhabditis elegans plk-1 gene Proteins 0.000 description 6
101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 6
101000818543 Homo sapiens Tyrosine-protein kinase ZAP-70 Proteins 0.000 description 6
206010020751 Hypersensitivity Diseases 0.000 description 6
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 6
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
108700020796 Oncogene Proteins 0.000 description 6
102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 6
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
229920002472 Starch Polymers 0.000 description 6
102000016663 Vascular Endothelial Growth Factor Receptor-3 Human genes 0.000 description 6
229910000147 aluminium phosphate Inorganic materials 0.000 description 6
238000003556 assay Methods 0.000 description 6
229940098773 bovine serum albumin Drugs 0.000 description 6
239000000969 carrier Substances 0.000 description 6
239000006184 cosolvent Substances 0.000 description 6
230000008021 deposition Effects 0.000 description 6
238000004128 high performance liquid chromatography Methods 0.000 description 6
238000000338 in vitro Methods 0.000 description 6
230000004054 inflammatory process Effects 0.000 description 6
239000008101 lactose Substances 0.000 description 6
239000007788 liquid Substances 0.000 description 6
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 6
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 6
229920000036 polyvinylpyrrolidone Polymers 0.000 description 6
230000001023 pro-angiogenic effect Effects 0.000 description 6
239000000047 product Substances 0.000 description 6
230000002062 proliferating effect Effects 0.000 description 6
238000011160 research Methods 0.000 description 6
206010039073 rheumatoid arthritis Diseases 0.000 description 6
230000011664 signaling Effects 0.000 description 6
229940001593 sodium carbonate Drugs 0.000 description 6
229910000029 sodium carbonate Inorganic materials 0.000 description 6
239000002904 solvent Substances 0.000 description 6
230000001988 toxicity Effects 0.000 description 6
231100000419 toxicity Toxicity 0.000 description 6
239000005483 tyrosine kinase inhibitor Substances 0.000 description 6
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
208000023275 Autoimmune disease Diseases 0.000 description 5
PLUBXMRUUVWRLT-UHFFFAOYSA-N Ethyl methanesulfonate Chemical compound CCOS(C)(=O)=O PLUBXMRUUVWRLT-UHFFFAOYSA-N 0.000 description 5
108010010803 Gelatin Proteins 0.000 description 5
206010018364 Glomerulonephritis Diseases 0.000 description 5
208000032843 Hemorrhage Diseases 0.000 description 5
206010061218 Inflammation Diseases 0.000 description 5
108010002350 Interleukin-2 Proteins 0.000 description 5
102000000588 Interleukin-2 Human genes 0.000 description 5
206010025323 Lymphomas Diseases 0.000 description 5
241000699666 Mus <mouse, genus> Species 0.000 description 5
235000008331 Pinus X rigitaeda Nutrition 0.000 description 5
235000011613 Pinus brutia Nutrition 0.000 description 5
241000018646 Pinus brutia Species 0.000 description 5
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 5
208000006011 Stroke Diseases 0.000 description 5
206010052779 Transplant rejections Diseases 0.000 description 5
102100021125 Tyrosine-protein kinase ZAP-70 Human genes 0.000 description 5
108091008605 VEGF receptors Proteins 0.000 description 5
108010073919 Vascular Endothelial Growth Factor D Proteins 0.000 description 5
102100038234 Vascular endothelial growth factor D Human genes 0.000 description 5
101100273808 Xenopus laevis cdk1-b gene Proteins 0.000 description 5
230000009471 action Effects 0.000 description 5
208000026935 allergic disease Diseases 0.000 description 5
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 5
230000001684 chronic effect Effects 0.000 description 5
230000003111 delayed effect Effects 0.000 description 5
230000001419 dependent effect Effects 0.000 description 5
230000003511 endothelial effect Effects 0.000 description 5
239000012530 fluid Substances 0.000 description 5
229920000159 gelatin Polymers 0.000 description 5
239000008273 gelatin Substances 0.000 description 5
229940014259 gelatin Drugs 0.000 description 5
235000019322 gelatine Nutrition 0.000 description 5
235000011852 gelatine desserts Nutrition 0.000 description 5
230000002209 hydrophobic effect Effects 0.000 description 5
230000009610 hypersensitivity Effects 0.000 description 5
210000000987 immune system Anatomy 0.000 description 5
230000003993 interaction Effects 0.000 description 5
239000011976 maleic acid Substances 0.000 description 5
201000006417 multiple sclerosis Diseases 0.000 description 5
NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 5
229920001223 polyethylene glycol Polymers 0.000 description 5
108090000765 processed proteins & peptides Proteins 0.000 description 5
238000000746 purification Methods 0.000 description 5
230000001105 regulatory effect Effects 0.000 description 5
208000037803 restenosis Diseases 0.000 description 5
210000002966 serum Anatomy 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
235000019698 starch Nutrition 0.000 description 5
239000008107 starch Substances 0.000 description 5
239000000829 suppository Substances 0.000 description 5
208000024891 symptom Diseases 0.000 description 5
208000011580 syndromic disease Diseases 0.000 description 5
238000012360 testing method Methods 0.000 description 5
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 5
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 4
206010001052 Acute respiratory distress syndrome Diseases 0.000 description 4
102100022014 Angiopoietin-1 receptor Human genes 0.000 description 4
102100034608 Angiopoietin-2 Human genes 0.000 description 4
PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 4
206010003445 Ascites Diseases 0.000 description 4
206010048962 Brain oedema Diseases 0.000 description 4
GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 4
208000005623 Carcinogenesis Diseases 0.000 description 4
208000011231 Crohn disease Diseases 0.000 description 4
102000004127 Cytokines Human genes 0.000 description 4
108090000695 Cytokines Proteins 0.000 description 4
206010012689 Diabetic retinopathy Diseases 0.000 description 4
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 4
108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 4
208000010412 Glaucoma Diseases 0.000 description 4
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
239000007995 HEPES buffer Substances 0.000 description 4
101000753291 Homo sapiens Angiopoietin-1 receptor Proteins 0.000 description 4
101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 4
101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
206010021143 Hypoxia Diseases 0.000 description 4
208000001344 Macular Edema Diseases 0.000 description 4
206010025415 Macular oedema Diseases 0.000 description 4
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
108010057466 NF-kappa B Proteins 0.000 description 4
102000003945 NF-kappa B Human genes 0.000 description 4
102100035194 Placenta growth factor Human genes 0.000 description 4
102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 4
108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 4
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 4
241000700159 Rattus Species 0.000 description 4
230000018199 S phase Effects 0.000 description 4
206010040047 Sepsis Diseases 0.000 description 4
239000007983 Tris buffer Substances 0.000 description 4
102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 4
150000007513 acids Chemical class 0.000 description 4
230000003213 activating effect Effects 0.000 description 4
238000010171 animal model Methods 0.000 description 4
239000005557 antagonist Substances 0.000 description 4
230000001772 anti-angiogenic effect Effects 0.000 description 4
239000000427 antigen Substances 0.000 description 4
108091007433 antigens Proteins 0.000 description 4
102000036639 antigens Human genes 0.000 description 4
206010003246 arthritis Diseases 0.000 description 4
HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 4
230000000903 blocking effect Effects 0.000 description 4
208000006752 brain edema Diseases 0.000 description 4
230000036952 cancer formation Effects 0.000 description 4
229910002091 carbon monoxide Inorganic materials 0.000 description 4
231100000504 carcinogenesis Toxicity 0.000 description 4
230000022131 cell cycle Effects 0.000 description 4
230000033077 cellular process Effects 0.000 description 4
230000006020 chronic inflammation Effects 0.000 description 4
238000004891 communication Methods 0.000 description 4
239000002299 complementary DNA Substances 0.000 description 4
239000012043 crude product Substances 0.000 description 4
238000011161 development Methods 0.000 description 4
230000018109 developmental process Effects 0.000 description 4
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 4
230000004069 differentiation Effects 0.000 description 4
239000008298 dragée Substances 0.000 description 4
239000000839 emulsion Substances 0.000 description 4
102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 4
108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 4
230000004761 fibrosis Effects 0.000 description 4
230000003394 haemopoietic effect Effects 0.000 description 4
230000007954 hypoxia Effects 0.000 description 4
230000003053 immunization Effects 0.000 description 4
238000002649 immunization Methods 0.000 description 4
230000002757 inflammatory effect Effects 0.000 description 4
208000014674 injury Diseases 0.000 description 4
210000003734 kidney Anatomy 0.000 description 4
201000010230 macular retinal edema Diseases 0.000 description 4
230000036210 malignancy Effects 0.000 description 4
239000011159 matrix material Substances 0.000 description 4
231100000682 maximum tolerated dose Toxicity 0.000 description 4
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 4
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 4
210000000056 organ Anatomy 0.000 description 4
239000003960 organic solvent Substances 0.000 description 4
239000008177 pharmaceutical agent Substances 0.000 description 4
239000012071 phase Substances 0.000 description 4
125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 4
125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 4
230000036470 plasma concentration Effects 0.000 description 4
239000000843 powder Substances 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
238000012552 review Methods 0.000 description 4
239000011734 sodium Substances 0.000 description 4
235000009518 sodium iodide Nutrition 0.000 description 4
239000003381 stabilizer Substances 0.000 description 4
125000005504 styryl group Chemical group 0.000 description 4
238000006467 substitution reaction Methods 0.000 description 4
235000000346 sugar Nutrition 0.000 description 4
230000009885 systemic effect Effects 0.000 description 4
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
230000008733 trauma Effects 0.000 description 4
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 3
WEJHBEDHLLBJFW-UHFFFAOYSA-N 4-(trifluoromethyl)benzamide Chemical compound NC(=O)C1=CC=C(C(F)(F)F)C=C1 WEJHBEDHLLBJFW-UHFFFAOYSA-N 0.000 description 3
102100034594 Angiopoietin-1 Human genes 0.000 description 3
108010009906 Angiopoietins Proteins 0.000 description 3
102000009840 Angiopoietins Human genes 0.000 description 3
201000001320 Atherosclerosis Diseases 0.000 description 3
206010006187 Breast cancer Diseases 0.000 description 3
208000026310 Breast neoplasm Diseases 0.000 description 3
102000016736 Cyclin Human genes 0.000 description 3
108050006400 Cyclin Proteins 0.000 description 3
102000002427 Cyclin B Human genes 0.000 description 3
108010068150 Cyclin B Proteins 0.000 description 3
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
101100481404 Danio rerio tie1 gene Proteins 0.000 description 3
206010063045 Effusion Diseases 0.000 description 3
201000009273 Endometriosis Diseases 0.000 description 3
208000009386 Experimental Arthritis Diseases 0.000 description 3
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
108091008794 FGF receptors Proteins 0.000 description 3
102100031706 Fibroblast growth factor 1 Human genes 0.000 description 3
206010017533 Fungal infection Diseases 0.000 description 3
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
208000007514 Herpes zoster Diseases 0.000 description 3
241000238631 Hexapoda Species 0.000 description 3
241000282412 Homo Species 0.000 description 3
101000924552 Homo sapiens Angiopoietin-1 Proteins 0.000 description 3
101000924533 Homo sapiens Angiopoietin-2 Proteins 0.000 description 3
101001001487 Homo sapiens Phosphatidylinositol-glycan biosynthesis class F protein Proteins 0.000 description 3
208000022559 Inflammatory bowel disease Diseases 0.000 description 3
108010074328 Interferon-gamma Proteins 0.000 description 3
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 3
208000019693 Lung disease Diseases 0.000 description 3
101100481406 Mus musculus Tie1 gene Proteins 0.000 description 3
208000031888 Mycoses Diseases 0.000 description 3
FEDCLFOUBBVXTB-MXVIHJGJSA-N NC1=C2C(=NC=N1)N(N=C2C2=CC(=C(C=C2)NC(C2=C(C=C(C=C2)C(F)(F)F)F)=O)OC)[C@@H]2CC[C@H](CC2)N2CCOCC2 Chemical compound NC1=C2C(=NC=N1)N(N=C2C2=CC(=C(C=C2)NC(C2=C(C=C(C=C2)C(F)(F)F)F)=O)OC)[C@@H]2CC[C@H](CC2)N2CCOCC2 FEDCLFOUBBVXTB-MXVIHJGJSA-N 0.000 description 3
208000001132 Osteoporosis Diseases 0.000 description 3
206010053869 POEMS syndrome Diseases 0.000 description 3
241000700639 Parapoxvirus Species 0.000 description 3
206010035226 Plasma cell myeloma Diseases 0.000 description 3
239000002202 Polyethylene glycol Substances 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
239000013504 Triton X-100 Substances 0.000 description 3
229920004890 Triton X-100 Polymers 0.000 description 3
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 3
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
102100039037 Vascular endothelial growth factor A Human genes 0.000 description 3
230000002159 abnormal effect Effects 0.000 description 3
239000013543 active substance Substances 0.000 description 3
239000000654 additive Substances 0.000 description 3
125000001931 aliphatic group Chemical group 0.000 description 3
208000007502 anemia Diseases 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
230000035578 autophosphorylation Effects 0.000 description 3
230000001580 bacterial effect Effects 0.000 description 3
230000006696 biosynthetic metabolic pathway Effects 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
125000004432 carbon atom Chemical group C* 0.000 description 3
125000004181 carboxyalkyl group Chemical group 0.000 description 3
230000003197 catalytic effect Effects 0.000 description 3
238000000423 cell based assay Methods 0.000 description 3
238000004113 cell culture Methods 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
208000037976 chronic inflammation Diseases 0.000 description 3
230000007882 cirrhosis Effects 0.000 description 3
208000019425 cirrhosis of liver Diseases 0.000 description 3
238000007796 conventional method Methods 0.000 description 3
238000002425 crystallisation Methods 0.000 description 3
230000008025 crystallization Effects 0.000 description 3
230000001086 cytosolic effect Effects 0.000 description 3
206010012601 diabetes mellitus Diseases 0.000 description 3
125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 3
235000021186 dishes Nutrition 0.000 description 3
238000006073 displacement reaction Methods 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
201000002491 encephalomyelitis Diseases 0.000 description 3
229940011871 estrogen Drugs 0.000 description 3
239000000262 estrogen Substances 0.000 description 3
DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 3
210000002744 extracellular matrix Anatomy 0.000 description 3
238000000605 extraction Methods 0.000 description 3
210000000416 exudates and transudate Anatomy 0.000 description 3
102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 description 3
239000000706 filtrate Substances 0.000 description 3
238000009472 formulation Methods 0.000 description 3
239000000499 gel Substances 0.000 description 3
230000012010 growth Effects 0.000 description 3
229920000669 heparin Polymers 0.000 description 3
229960002897 heparin Drugs 0.000 description 3
230000006872 improvement Effects 0.000 description 3
230000001939 inductive effect Effects 0.000 description 3
230000028709 inflammatory response Effects 0.000 description 3
230000031146 intracellular signal transduction Effects 0.000 description 3
230000000302 ischemic effect Effects 0.000 description 3
229940043355 kinase inhibitor Drugs 0.000 description 3
239000010410 layer Substances 0.000 description 3
GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 3
108010052968 leupeptin Proteins 0.000 description 3
230000000670 limiting effect Effects 0.000 description 3
239000002502 liposome Substances 0.000 description 3
239000006166 lysate Substances 0.000 description 3
235000019359 magnesium stearate Nutrition 0.000 description 3
108020004999 messenger RNA Proteins 0.000 description 3
238000013508 migration Methods 0.000 description 3
210000001616 monocyte Anatomy 0.000 description 3
238000010172 mouse model Methods 0.000 description 3
230000035772 mutation Effects 0.000 description 3
230000001613 neoplastic effect Effects 0.000 description 3
210000004940 nucleus Anatomy 0.000 description 3
231100000590 oncogenic Toxicity 0.000 description 3
230000002246 oncogenic effect Effects 0.000 description 3
201000008482 osteoarthritis Diseases 0.000 description 3
239000003757 phosphotransferase inhibitor Substances 0.000 description 3
DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 3
HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 description 3
235000019260 propionic acid Nutrition 0.000 description 3
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 3
239000011535 reaction buffer Substances 0.000 description 3
201000000306 sarcoidosis Diseases 0.000 description 3
238000010898 silica gel chromatography Methods 0.000 description 3
239000000600 sorbitol Substances 0.000 description 3
235000010356 sorbitol Nutrition 0.000 description 3
150000008163 sugars Chemical class 0.000 description 3
239000004094 surface-active agent Substances 0.000 description 3
201000004595 synovitis Diseases 0.000 description 3
206010043778 thyroiditis Diseases 0.000 description 3
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
208000006542 von Hippel-Lindau disease Diseases 0.000 description 3
230000004584 weight gain Effects 0.000 description 3
235000019786 weight gain Nutrition 0.000 description 3
238000001262 western blot Methods 0.000 description 3
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
BMEMBBFDTYHTLH-UHFFFAOYSA-N 1-(2-methoxyethyl)piperazine Chemical compound COCCN1CCNCC1 BMEMBBFDTYHTLH-UHFFFAOYSA-N 0.000 description 2
FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
PBLZLIFKVPJDCO-UHFFFAOYSA-N 12-aminododecanoic acid Chemical compound NCCCCCCCCCCCC(O)=O PBLZLIFKVPJDCO-UHFFFAOYSA-N 0.000 description 2
VFHUJFBEFDVZPJ-UHFFFAOYSA-N 1h-indole-2-carboxamide Chemical compound C1=CC=C2NC(C(=O)N)=CC2=C1 VFHUJFBEFDVZPJ-UHFFFAOYSA-N 0.000 description 2
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 2
125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 2
WFCSWCVEJLETKA-UHFFFAOYSA-N 2-piperazin-1-ylethanol Chemical compound OCCN1CCNCC1 WFCSWCVEJLETKA-UHFFFAOYSA-N 0.000 description 2
LDSQQXKSEFZAPE-UHFFFAOYSA-N 2-piperidin-4-ylethanol Chemical compound OCCC1CCNCC1 LDSQQXKSEFZAPE-UHFFFAOYSA-N 0.000 description 2
UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 2
KDHWOCLBMVSZPG-UHFFFAOYSA-N 3-imidazol-1-ylpropan-1-amine Chemical compound NCCCN1C=CN=C1 KDHWOCLBMVSZPG-UHFFFAOYSA-N 0.000 description 2
HQAIUXZORKJOJY-UHFFFAOYSA-N 3-iodo-2h-pyrazolo[3,4-d]pyrimidin-4-amine Chemical compound NC1=NC=NC2=NNC(I)=C12 HQAIUXZORKJOJY-UHFFFAOYSA-N 0.000 description 2
LUSJXEMIZFYDSZ-UHFFFAOYSA-N 3-iodo-2h-pyrazolo[3,4-d]pyrimidine Chemical compound C1=NC=C2C(I)=NNC2=N1 LUSJXEMIZFYDSZ-UHFFFAOYSA-N 0.000 description 2
FAXDZWQIWUSWJH-UHFFFAOYSA-N 3-methoxypropan-1-amine Chemical compound COCCCN FAXDZWQIWUSWJH-UHFFFAOYSA-N 0.000 description 2
UCFSYHMCKWNKAH-UHFFFAOYSA-N 4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound CC1(C)OBOC1(C)C UCFSYHMCKWNKAH-UHFFFAOYSA-N 0.000 description 2
DLAJQEFZFUKNBV-UHFFFAOYSA-N 4,4,5,5-tetramethyl-n-phenyl-1,3,2-dioxaborolan-2-amine Chemical compound O1C(C)(C)C(C)(C)OB1NC1=CC=CC=C1 DLAJQEFZFUKNBV-UHFFFAOYSA-N 0.000 description 2
BLFRQYKZFKYQLO-UHFFFAOYSA-N 4-aminobutan-1-ol Chemical compound NCCCCO BLFRQYKZFKYQLO-UHFFFAOYSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
108010039627 Aprotinin Proteins 0.000 description 2
208000035143 Bacterial infection Diseases 0.000 description 2
201000004569 Blindness Diseases 0.000 description 2
208000020084 Bone disease Diseases 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
241000283707 Capra Species 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
102000011022 Chorionic Gonadotropin Human genes 0.000 description 2
108010062540 Chorionic Gonadotropin Proteins 0.000 description 2
108091026890 Coding region Proteins 0.000 description 2
206010009900 Colitis ulcerative Diseases 0.000 description 2
206010010741 Conjunctivitis Diseases 0.000 description 2
229920002261 Corn starch Polymers 0.000 description 2
102000002554 Cyclin A Human genes 0.000 description 2
108010068192 Cyclin A Proteins 0.000 description 2
102000003909 Cyclin E Human genes 0.000 description 2
108090000257 Cyclin E Proteins 0.000 description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
206010054044 Diabetic microangiopathy Diseases 0.000 description 2
206010051392 Diapedesis Diseases 0.000 description 2
XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 description 2
101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
102000009465 Growth Factor Receptors Human genes 0.000 description 2
108010009202 Growth Factor Receptors Proteins 0.000 description 2
102100021866 Hepatocyte growth factor Human genes 0.000 description 2
208000009889 Herpes Simplex Diseases 0.000 description 2
101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 2
108010070875 Human Immunodeficiency Virus tat Gene Products Proteins 0.000 description 2
241000725303 Human immunodeficiency virus Species 0.000 description 2
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 2
208000001953 Hypotension Diseases 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
206010061216 Infarction Diseases 0.000 description 2
102100037850 Interferon gamma Human genes 0.000 description 2
208000007766 Kaposi sarcoma Diseases 0.000 description 2
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
208000016604 Lyme disease Diseases 0.000 description 2
206010025538 Malignant ascites Diseases 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
206010027476 Metastases Diseases 0.000 description 2
206010027452 Metastases to bone Diseases 0.000 description 2
102100023482 Mitogen-activated protein kinase 14 Human genes 0.000 description 2
102000047918 Myelin Basic Human genes 0.000 description 2
101710107068 Myelin basic protein Proteins 0.000 description 2
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
206010029260 Neuroblastoma Diseases 0.000 description 2
241000700635 Orf virus Species 0.000 description 2
208000010191 Osteitis Deformans Diseases 0.000 description 2
101150093908 PDGFRB gene Proteins 0.000 description 2
208000027868 Paget disease Diseases 0.000 description 2
206010034277 Pemphigoid Diseases 0.000 description 2
208000005228 Pericardial Effusion Diseases 0.000 description 2
206010036049 Polycystic ovaries Diseases 0.000 description 2
108010029485 Protein Isoforms Proteins 0.000 description 2
102000001708 Protein Isoforms Human genes 0.000 description 2
108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 2
102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 2
KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
206010038848 Retinal detachment Diseases 0.000 description 2
208000017442 Retinal disease Diseases 0.000 description 2
201000000582 Retinoblastoma Diseases 0.000 description 2
206010038923 Retinopathy Diseases 0.000 description 2
241000283984 Rodentia Species 0.000 description 2
108060006706 SRC Proteins 0.000 description 2
102000001332 SRC Human genes 0.000 description 2
206010039491 Sarcoma Diseases 0.000 description 2
206010039705 Scleritis Diseases 0.000 description 2
229920002684 Sepharose Polymers 0.000 description 2
206010040070 Septic Shock Diseases 0.000 description 2
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
208000005718 Stomach Neoplasms Diseases 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
230000006044 T cell activation Effects 0.000 description 2
YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
108010000499 Thromboplastin Proteins 0.000 description 2
102000002262 Thromboplastin Human genes 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
201000005485 Toxoplasmosis Diseases 0.000 description 2
108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
201000006704 Ulcerative Colitis Diseases 0.000 description 2
206010046851 Uveitis Diseases 0.000 description 2
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 2
208000036142 Viral infection Diseases 0.000 description 2
241000700605 Viruses Species 0.000 description 2
206010047663 Vitritis Diseases 0.000 description 2
DWAYENIPKPKKMV-ILKKLZGPSA-N [(2s)-3-(1h-imidazol-3-ium-4-yl)-1-methoxy-1-oxopropan-2-yl]azanium;dichloride Chemical compound Cl.Cl.COC(=O)[C@@H](N)CC1=CN=CN1 DWAYENIPKPKKMV-ILKKLZGPSA-N 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
210000001789 adipocyte Anatomy 0.000 description 2
238000001261 affinity purification Methods 0.000 description 2
239000000556 agonist Substances 0.000 description 2
125000005078 alkoxycarbonylalkyl group Chemical group 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
125000000539 amino acid group Chemical group 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000006427 angiogenic response Effects 0.000 description 2
230000006907 apoptotic process Effects 0.000 description 2
238000013459 approach Methods 0.000 description 2
229960004405 aprotinin Drugs 0.000 description 2
239000012131 assay buffer Substances 0.000 description 2
208000006673 asthma Diseases 0.000 description 2
125000004429 atom Chemical group 0.000 description 2
230000003305 autocrine Effects 0.000 description 2
210000003719 b-lymphocyte Anatomy 0.000 description 2
208000022362 bacterial infectious disease Diseases 0.000 description 2
UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
125000002619 bicyclic group Chemical group 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
230000000740 bleeding effect Effects 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
230000006369 cell cycle progression Effects 0.000 description 2
230000024245 cell differentiation Effects 0.000 description 2
230000003915 cell function Effects 0.000 description 2
230000010261 cell growth Effects 0.000 description 2
230000012292 cell migration Effects 0.000 description 2
230000036755 cellular response Effects 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
230000002490 cerebral effect Effects 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
238000012761 co-transfection Methods 0.000 description 2
238000010276 construction Methods 0.000 description 2
239000008120 corn starch Substances 0.000 description 2
229940099112 cornstarch Drugs 0.000 description 2
125000004966 cyanoalkyl group Chemical group 0.000 description 2
229940127089 cytotoxic agent Drugs 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000007850 degeneration Effects 0.000 description 2
239000008121 dextrose Substances 0.000 description 2
201000009101 diabetic angiopathy Diseases 0.000 description 2
FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
239000000539 dimer Substances 0.000 description 2
238000006471 dimerization reaction Methods 0.000 description 2
IUNMPGNGSSIWFP-UHFFFAOYSA-N dimethylaminopropylamine Chemical compound CN(C)CCCN IUNMPGNGSSIWFP-UHFFFAOYSA-N 0.000 description 2
208000037765 diseases and disorders Diseases 0.000 description 2
230000002526 effect on cardiovascular system Effects 0.000 description 2
210000003038 endothelium Anatomy 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
239000013604 expression vector Substances 0.000 description 2
239000010685 fatty oil Substances 0.000 description 2
238000003818 flash chromatography Methods 0.000 description 2
125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 2
239000012458 free base Substances 0.000 description 2
238000001030 gas--liquid chromatography Methods 0.000 description 2
239000008187 granular material Substances 0.000 description 2
239000000833 heterodimer Substances 0.000 description 2
238000005734 heterodimerization reaction Methods 0.000 description 2
125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 2
102000058223 human VEGFA Human genes 0.000 description 2
229940084986 human chorionic gonadotropin Drugs 0.000 description 2
208000013653 hyalitis Diseases 0.000 description 2
125000004356 hydroxy functional group Chemical group O* 0.000 description 2
230000036543 hypotension Effects 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
238000011534 incubation Methods 0.000 description 2
230000006698 induction Effects 0.000 description 2
230000007574 infarction Effects 0.000 description 2
238000001802 infusion Methods 0.000 description 2
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 2
238000010255 intramuscular injection Methods 0.000 description 2
239000007927 intramuscular injection Substances 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
238000000021 kinase assay Methods 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
238000013532 laser treatment Methods 0.000 description 2
208000032839 leukemia Diseases 0.000 description 2
238000004811 liquid chromatography Methods 0.000 description 2
231100000053 low toxicity Toxicity 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
206010025135 lupus erythematosus Diseases 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
208000002780 macular degeneration Diseases 0.000 description 2
229910052943 magnesium sulfate Inorganic materials 0.000 description 2
235000019341 magnesium sulphate Nutrition 0.000 description 2
208000027202 mammary Paget disease Diseases 0.000 description 2
108010082117 matrigel Proteins 0.000 description 2
238000005259 measurement Methods 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
239000003226 mitogen Substances 0.000 description 2
230000002297 mitogenic effect Effects 0.000 description 2
238000002156 mixing Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000000051 modifying effect Effects 0.000 description 2
125000006203 morpholinoethyl group Chemical group [H]C([H])(*)C([H])([H])N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H] 0.000 description 2
125000001064 morpholinomethyl group Chemical group [H]C([H])(*)N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H] 0.000 description 2
201000000050 myeloid neoplasm Diseases 0.000 description 2
208000001491 myopia Diseases 0.000 description 2
230000004379 myopia Effects 0.000 description 2
SSXSLXIYJFPWRR-UHFFFAOYSA-N n-[4-[4-amino-1-[2-(dimethylamino)ethyl]pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methylindole-2-carboxamide Chemical compound C1=NC(N)=C2C(C=3C=C(C(=CC=3)NC(=O)C=3N(C4=CC=CC=C4C=3)C)OC)=NN(CCN(C)C)C2=N1 SSXSLXIYJFPWRR-UHFFFAOYSA-N 0.000 description 2
RWIVICVCHVMHMU-UHFFFAOYSA-N n-aminoethylmorpholine Chemical compound NCCN1CCOCC1 RWIVICVCHVMHMU-UHFFFAOYSA-N 0.000 description 2
210000002569 neuron Anatomy 0.000 description 2
125000006574 non-aromatic ring group Chemical group 0.000 description 2
102000037979 non-receptor tyrosine kinases Human genes 0.000 description 2
108091008046 non-receptor tyrosine kinases Proteins 0.000 description 2
230000000414 obstructive effect Effects 0.000 description 2
210000002997 osteoclast Anatomy 0.000 description 2
208000002865 osteopetrosis Diseases 0.000 description 2
230000002611 ovarian Effects 0.000 description 2
230000002018 overexpression Effects 0.000 description 2
CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
125000004043 oxo group Chemical group O=* 0.000 description 2
108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 2
KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 2
239000008188 pellet Substances 0.000 description 2
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
229940080469 phosphocellulose Drugs 0.000 description 2
LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
239000004033 plastic Substances 0.000 description 2
208000030761 polycystic kidney disease Diseases 0.000 description 2
201000010065 polycystic ovary syndrome Diseases 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
229940068968 polysorbate 80 Drugs 0.000 description 2
229920000053 polysorbate 80 Polymers 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
201000011461 pre-eclampsia Diseases 0.000 description 2
230000002265 prevention Effects 0.000 description 2
OYRRZWATULMEPF-UHFFFAOYSA-N pyrimidin-4-amine Chemical compound NC1=CC=NC=N1 OYRRZWATULMEPF-UHFFFAOYSA-N 0.000 description 2
150000003246 quinazolines Chemical class 0.000 description 2
230000005855 radiation Effects 0.000 description 2
230000002285 radioactive effect Effects 0.000 description 2
230000004264 retinal detachment Effects 0.000 description 2
201000009410 rhabdomyosarcoma Diseases 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
238000000926 separation method Methods 0.000 description 2
230000036303 septic shock Effects 0.000 description 2
239000000741 silica gel Substances 0.000 description 2
229910002027 silica gel Inorganic materials 0.000 description 2
239000000377 silicon dioxide Substances 0.000 description 2
150000003384 small molecules Chemical class 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
239000012312 sodium hydride Substances 0.000 description 2
229910000104 sodium hydride Inorganic materials 0.000 description 2
239000012453 solvate Substances 0.000 description 2
241000894007 species Species 0.000 description 2
201000000498 stomach carcinoma Diseases 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
235000012222 talc Nutrition 0.000 description 2
238000004809 thin layer chromatography Methods 0.000 description 2
125000005309 thioalkoxy group Chemical group 0.000 description 2
125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
238000001890 transfection Methods 0.000 description 2
239000012096 transfection reagent Substances 0.000 description 2
238000012546 transfer Methods 0.000 description 2
230000009261 transgenic effect Effects 0.000 description 2
230000007704 transition Effects 0.000 description 2
230000014616 translation Effects 0.000 description 2
238000002054 transplantation Methods 0.000 description 2
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 2
IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 2
230000006459 vascular development Effects 0.000 description 2
230000004862 vasculogenesis Effects 0.000 description 2
239000013598 vector Substances 0.000 description 2
230000009385 viral infection Effects 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
230000029663 wound healing Effects 0.000 description 2
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical compound OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 description 1
LPBSHGLDBQBSPI-YFKPBYRVSA-N (2s)-2-amino-4,4-dimethylpentanoic acid Chemical compound CC(C)(C)C[C@H](N)C(O)=O LPBSHGLDBQBSPI-YFKPBYRVSA-N 0.000 description 1
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
WQBHLYNGQCLNBY-SPIKMXEPSA-N (Z)-but-2-enedioic acid 1H-indole-2-carboxamide Chemical compound OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O.c1cccc2[nH]c(C(=O)N)cc21 WQBHLYNGQCLNBY-SPIKMXEPSA-N 0.000 description 1
PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
CYDRRUIHHLXFKW-UHFFFAOYSA-N 1-methylindole-2-carboxamide Chemical compound C1=CC=C2N(C)C(C(N)=O)=CC2=C1 CYDRRUIHHLXFKW-UHFFFAOYSA-N 0.000 description 1
PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 1
VOXZDWNPVJITMN-UHFFFAOYSA-N 13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2C3CCC(C)(C(CC4)O)C4C3CCC2=C1 VOXZDWNPVJITMN-UHFFFAOYSA-N 0.000 description 1
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Substances C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 1
FRUWMYWEARDNTC-UHFFFAOYSA-N 2,3,3a,4-tetrahydro-1h-indole Chemical class C1C=CC=C2NCCC21 FRUWMYWEARDNTC-UHFFFAOYSA-N 0.000 description 1
PCEJMSIIDXUDSN-UHFFFAOYSA-N 2,4-diaminopentanoic acid Chemical compound CC(N)CC(N)C(O)=O PCEJMSIIDXUDSN-UHFFFAOYSA-N 0.000 description 1
YXVVDWURKALCCT-UHFFFAOYSA-N 2-(4-amino-3-iodopyrazolo[3,4-d]pyrimidin-1-yl)ethanol Chemical compound NC1=NC=NC2=C1C(I)=NN2CCO YXVVDWURKALCCT-UHFFFAOYSA-N 0.000 description 1
TXHAHOVNFDVCCC-UHFFFAOYSA-N 2-(tert-butylazaniumyl)acetate Chemical compound CC(C)(C)NCC(O)=O TXHAHOVNFDVCCC-UHFFFAOYSA-N 0.000 description 1
QWCKQJZIFLGMSD-UHFFFAOYSA-N 2-Aminobutanoic acid Natural products CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 1
NBNVUAGGGIPDQJ-UHFFFAOYSA-N 2-[4-amino-3-[3-methoxy-4-[(1-methylindole-2-carbonyl)amino]phenyl]pyrazolo[3,4-d]pyrimidin-1-yl]ethyl methanesulfonate Chemical compound C1=NC(N)=C2C(C=3C=C(C(=CC=3)NC(=O)C=3N(C4=CC=CC=C4C=3)C)OC)=NN(CCOS(C)(=O)=O)C2=N1 NBNVUAGGGIPDQJ-UHFFFAOYSA-N 0.000 description 1
UHQFXIWMAQOCAN-UHFFFAOYSA-N 2-amino-1,3-dihydroindene-2-carboxylic acid Chemical compound C1=CC=C2CC(N)(C(O)=O)CC2=C1 UHQFXIWMAQOCAN-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
LDLCZOVUSADOIV-UHFFFAOYSA-N 2-bromoethanol Chemical compound OCCBr LDLCZOVUSADOIV-UHFFFAOYSA-N 0.000 description 1
ASUDFOJKTJLAIK-UHFFFAOYSA-N 2-methoxyethanamine Chemical compound COCCN ASUDFOJKTJLAIK-UHFFFAOYSA-N 0.000 description 1
WIQRSJOCVVPMPS-UHFFFAOYSA-N 3-(1h-indol-2-yl)pyrrole-2,5-dione Chemical class O=C1NC(=O)C(C=2NC3=CC=CC=C3C=2)=C1 WIQRSJOCVVPMPS-UHFFFAOYSA-N 0.000 description 1
NUFBIAUZAMHTSP-UHFFFAOYSA-N 3-(n-morpholino)-2-hydroxypropanesulfonic acid Chemical compound OS(=O)(=O)CC(O)CN1CCOCC1 NUFBIAUZAMHTSP-UHFFFAOYSA-N 0.000 description 1
WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
AUQWULHNUIMUIE-UHFFFAOYSA-N 4-(4-amino-3-iodopyrazolo[3,4-d]pyrimidin-1-yl)benzaldehyde Chemical compound N1=C(I)C=2C(N)=NC=NC=2N1C1=CC=C(C=O)C=C1 AUQWULHNUIMUIE-UHFFFAOYSA-N 0.000 description 1
SINQIEAULQKUPD-UHFFFAOYSA-N 4-[4-(6-methoxy-2-naphthalenyl)-2-(4-methylsulfinylphenyl)-1H-imidazol-5-yl]pyridine Chemical compound C1=CC2=CC(OC)=CC=C2C=C1C=1N=C(C=2C=CC(=CC=2)S(C)=O)NC=1C1=CC=NC=C1 SINQIEAULQKUPD-UHFFFAOYSA-N 0.000 description 1
CMUHFUGDYMFHEI-QMMMGPOBSA-N 4-amino-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N)C=C1 CMUHFUGDYMFHEI-QMMMGPOBSA-N 0.000 description 1
UOQXIWFBQSVDPP-UHFFFAOYSA-N 4-fluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C=C1 UOQXIWFBQSVDPP-UHFFFAOYSA-N 0.000 description 1
VUDOCFDQOADWOB-UHFFFAOYSA-N 7h-purine;quinazoline Chemical class C1=NC=C2NC=NC2=N1.N1=CN=CC2=CC=CC=C21 VUDOCFDQOADWOB-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
208000030090 Acute Disease Diseases 0.000 description 1
206010001258 Adenoviral infections Diseases 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
206010002198 Anaphylactic reaction Diseases 0.000 description 1
108010048036 Angiopoietin-2 Proteins 0.000 description 1
201000002909 Aspergillosis Diseases 0.000 description 1
241000228212 Aspergillus Species 0.000 description 1
208000036641 Aspergillus infections Diseases 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
OGBVRMYSNSKIEF-UHFFFAOYSA-N Benzylphosphonic acid Chemical class OP(O)(=O)CC1=CC=CC=C1 OGBVRMYSNSKIEF-UHFFFAOYSA-N 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
208000006386 Bone Resorption Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
101100481403 Bos taurus TIE1 gene Proteins 0.000 description 1
101150047144 CDC28 gene Proteins 0.000 description 1
WEYKVZIGUIPOSV-UHFFFAOYSA-N CN1C2=CC=CC=C2CC1(C3=C(C=C(C=C3)C4=NN(C5=NC=NC(=C45)N)CCN6CCOCC6)OC)C(=O)N Chemical compound CN1C2=CC=CC=C2CC1(C3=C(C=C(C=C3)C4=NN(C5=NC=NC(=C45)N)CCN6CCOCC6)OC)C(=O)N WEYKVZIGUIPOSV-UHFFFAOYSA-N 0.000 description 1
IQPCGWBFWRYTAE-UHFFFAOYSA-N CN1C2=CC=CC=C2CC1(C3=C(C=C(C=C3)C4=NN(C5=NC=NC(=C45)N)CCO)OC)C(=O)N Chemical compound CN1C2=CC=CC=C2CC1(C3=C(C=C(C=C3)C4=NN(C5=NC=NC(=C45)N)CCO)OC)C(=O)N IQPCGWBFWRYTAE-UHFFFAOYSA-N 0.000 description 1
101100005789 Caenorhabditis elegans cdk-4 gene Proteins 0.000 description 1
235000002566 Capsicum Nutrition 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
208000014882 Carotid artery disease Diseases 0.000 description 1
208000003732 Cat-scratch disease Diseases 0.000 description 1
229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
206010008190 Cerebrovascular accident Diseases 0.000 description 1
102000019034 Chemokines Human genes 0.000 description 1
108010012236 Chemokines Proteins 0.000 description 1
208000005590 Choroidal Neovascularization Diseases 0.000 description 1
206010060823 Choroidal neovascularisation Diseases 0.000 description 1
208000035970 Chromosome Breakpoints Diseases 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
102000000503 Collagen Type II Human genes 0.000 description 1
108010041390 Collagen Type II Proteins 0.000 description 1
102000003910 Cyclin D Human genes 0.000 description 1
108090000259 Cyclin D Proteins 0.000 description 1
108010025454 Cyclin-Dependent Kinase 5 Proteins 0.000 description 1
102100032857 Cyclin-dependent kinase 1 Human genes 0.000 description 1
101710106279 Cyclin-dependent kinase 1 Proteins 0.000 description 1
102100026805 Cyclin-dependent-like kinase 5 Human genes 0.000 description 1
OABOXRPGTFRBFZ-IMJSIDKUSA-N Cys-Cys Chemical compound SC[C@H](N)C(=O)N[C@@H](CS)C(O)=O OABOXRPGTFRBFZ-IMJSIDKUSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
QWCKQJZIFLGMSD-GSVOUGTGSA-N D-alpha-aminobutyric acid Chemical compound CC[C@@H](N)C(O)=O QWCKQJZIFLGMSD-GSVOUGTGSA-N 0.000 description 1
FEWJPZIEWOKRBE-LWMBPPNESA-L D-tartrate(2-) Chemical compound [O-]C(=O)[C@@H](O)[C@H](O)C([O-])=O FEWJPZIEWOKRBE-LWMBPPNESA-L 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
230000006820 DNA synthesis Effects 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
208000002249 Diabetes Complications Diseases 0.000 description 1
206010012655 Diabetic complications Diseases 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
239000004338 Dichlorodifluoromethane Substances 0.000 description 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
108060006698 EGF receptor Proteins 0.000 description 1
208000019878 Eales disease Diseases 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
241000792859 Enema Species 0.000 description 1
208000006168 Ewing Sarcoma Diseases 0.000 description 1
108010073385 Fibrin Proteins 0.000 description 1
102000009123 Fibrin Human genes 0.000 description 1
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical group CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 1
102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
201000008808 Fibrosarcoma Diseases 0.000 description 1
KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
206010017076 Fracture Diseases 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
241000233866 Fungi Species 0.000 description 1
102000001267 GSK3 Human genes 0.000 description 1
108060006662 GSK3 Proteins 0.000 description 1
206010017711 Gangrene Diseases 0.000 description 1
241000206672 Gelidium Species 0.000 description 1
102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 description 1
108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 description 1
206010018498 Goitre Diseases 0.000 description 1
102000006771 Gonadotropins Human genes 0.000 description 1
108010086677 Gonadotropins Proteins 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
238000010268 HPLC based assay Methods 0.000 description 1
241000589989 Helicobacter Species 0.000 description 1
102000001554 Hemoglobins Human genes 0.000 description 1
108010054147 Hemoglobins Proteins 0.000 description 1
208000031953 Hereditary hemorrhagic telangiectasia Diseases 0.000 description 1
108010033040 Histones Proteins 0.000 description 1
208000017604 Hodgkin disease Diseases 0.000 description 1
208000010747 Hodgkins lymphoma Diseases 0.000 description 1
101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 description 1
101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 1
101001005128 Homo sapiens LIM domain kinase 1 Proteins 0.000 description 1
101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 description 1
101001092185 Homo sapiens Regulator of cell cycle RGCC Proteins 0.000 description 1
101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 description 1
101000742596 Homo sapiens Vascular endothelial growth factor C Proteins 0.000 description 1
101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 description 1
241000701806 Human papillomavirus Species 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
208000037147 Hypercalcaemia Diseases 0.000 description 1
208000002682 Hyperkalemia Diseases 0.000 description 1
206010051151 Hyperviscosity syndrome Diseases 0.000 description 1
102000038455 IGF Type 1 Receptor Human genes 0.000 description 1
102000008070 Interferon-gamma Human genes 0.000 description 1
108010002352 Interleukin-1 Proteins 0.000 description 1
102100036342 Interleukin-1 receptor-associated kinase 1 Human genes 0.000 description 1
101710199015 Interleukin-1 receptor-associated kinase 1 Proteins 0.000 description 1
102100036433 Interleukin-1 receptor-associated kinase-like 2 Human genes 0.000 description 1
101710182491 Interleukin-1 receptor-associated kinase-like 2 Proteins 0.000 description 1
102000015617 Janus Kinases Human genes 0.000 description 1
108010024121 Janus Kinases Proteins 0.000 description 1
208000002260 Keloid Diseases 0.000 description 1
206010023330 Keloid scar Diseases 0.000 description 1
AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
102100026023 LIM domain kinase 1 Human genes 0.000 description 1
241000255777 Lepidoptera Species 0.000 description 1
102000003960 Ligases Human genes 0.000 description 1
108090000364 Ligases Proteins 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
102000043136 MAP kinase family Human genes 0.000 description 1
108091054455 MAP kinase family Proteins 0.000 description 1
108010058398 Macrophage Colony-Stimulating Factor Receptor Proteins 0.000 description 1
102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 1
101710150918 Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 1
206010025421 Macule Diseases 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
206010027458 Metastases to lung Diseases 0.000 description 1
239000012359 Methanesulfonyl chloride Substances 0.000 description 1
208000034578 Multiple myelomas Diseases 0.000 description 1
241001529936 Murinae Species 0.000 description 1
101000851005 Mus musculus Vascular endothelial growth factor receptor 2 Proteins 0.000 description 1
101100268066 Mus musculus Zap70 gene Proteins 0.000 description 1
206010028372 Muscular weakness Diseases 0.000 description 1
HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
GDFAOVXKHJXLEI-VKHMYHEASA-N N-methyl-L-alanine Chemical compound C[NH2+][C@@H](C)C([O-])=O GDFAOVXKHJXLEI-VKHMYHEASA-N 0.000 description 1
XLBVNMSMFQMKEY-BYPYZUCNSA-N N-methyl-L-glutamic acid Chemical compound CN[C@H](C(O)=O)CCC(O)=O XLBVNMSMFQMKEY-BYPYZUCNSA-N 0.000 description 1
150000001204 N-oxides Chemical class 0.000 description 1
102000019148 NF-kappaB-inducing kinase activity proteins Human genes 0.000 description 1
108040008091 NF-kappaB-inducing kinase activity proteins Proteins 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
206010028851 Necrosis Diseases 0.000 description 1
102100028762 Neuropilin-1 Human genes 0.000 description 1
108090000772 Neuropilin-1 Proteins 0.000 description 1
102100028492 Neuropilin-2 Human genes 0.000 description 1
108090000770 Neuropilin-2 Proteins 0.000 description 1
101100258315 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) crc-1 gene Proteins 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 1
208000022873 Ocular disease Diseases 0.000 description 1
AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
102000016979 Other receptors Human genes 0.000 description 1
206010033266 Ovarian Hyperstimulation Syndrome Diseases 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
108091008606 PDGF receptors Proteins 0.000 description 1
101150038994 PDGFRA gene Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
206010061902 Pancreatic neoplasm Diseases 0.000 description 1
241001536563 Panus Species 0.000 description 1
208000034038 Pathologic Neovascularization Diseases 0.000 description 1
241001494479 Pecora Species 0.000 description 1
239000006002 Pepper Substances 0.000 description 1
208000008469 Peptic Ulcer Diseases 0.000 description 1
201000005702 Pertussis Diseases 0.000 description 1
PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
235000016761 Piper aduncum Nutrition 0.000 description 1
235000017804 Piper guineense Nutrition 0.000 description 1
244000203593 Piper nigrum Species 0.000 description 1
235000008184 Piper nigrum Nutrition 0.000 description 1
108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 1
102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 1
102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 1
206010035610 Pleural Neoplasms Diseases 0.000 description 1
208000002151 Pleural effusion Diseases 0.000 description 1
208000037062 Polyps Diseases 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
229920002642 Polysorbate 65 Polymers 0.000 description 1
208000005107 Premature Birth Diseases 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
102100037787 Protein-tyrosine kinase 2-beta Human genes 0.000 description 1
108700020978 Proto-Oncogene Proteins 0.000 description 1
102000052575 Proto-Oncogene Human genes 0.000 description 1
108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 1
102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 1
206010037423 Pulmonary oedema Diseases 0.000 description 1
101710141955 RAF proto-oncogene serine/threonine-protein kinase Proteins 0.000 description 1
102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 description 1
239000012083 RIPA buffer Substances 0.000 description 1
102100022419 RPA-interacting protein Human genes 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
229940078123 Ras inhibitor Drugs 0.000 description 1
101000851003 Rattus norvegicus Vascular endothelial growth factor receptor 2 Proteins 0.000 description 1
230000010799 Receptor Interactions Effects 0.000 description 1
229940127361 Receptor Tyrosine Kinase Inhibitors Drugs 0.000 description 1
102100035542 Regulator of cell cycle RGCC Human genes 0.000 description 1
206010063837 Reperfusion injury Diseases 0.000 description 1
206010038933 Retinopathy of prematurity Diseases 0.000 description 1
108090000829 Ribosome Inactivating Proteins Proteins 0.000 description 1
241000220317 Rosa Species 0.000 description 1
108050003452 SH2 domains Proteins 0.000 description 1
102000014400 SH2 domains Human genes 0.000 description 1
101150001535 SRC gene Proteins 0.000 description 1
241000218998 Salicaceae Species 0.000 description 1
108010077895 Sarcosine Proteins 0.000 description 1
208000034189 Sclerosis Diseases 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
101710172711 Structural protein Proteins 0.000 description 1
PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Natural products C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
108091008874 T cell receptors Proteins 0.000 description 1
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
108091082333 TEC family Proteins 0.000 description 1
102000042834 TEC family Human genes 0.000 description 1
108010090091 TIE-2 Receptor Proteins 0.000 description 1
102000012753 TIE-2 Receptor Human genes 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
102100035115 Testin Human genes 0.000 description 1
FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
108090000190 Thrombin Proteins 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
102100040247 Tumor necrosis factor Human genes 0.000 description 1
102100031358 Urokinase-type plasminogen activator Human genes 0.000 description 1
108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
108010073925 Vascular Endothelial Growth Factor B Proteins 0.000 description 1
108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 1
102100038217 Vascular endothelial growth factor B Human genes 0.000 description 1
206010052428 Wound Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
108700025690 abl Genes Proteins 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
JYVSZCNTYXUUGH-UHFFFAOYSA-N acetic acid;benzamide Chemical compound CC(O)=O.NC(=O)C1=CC=CC=C1 JYVSZCNTYXUUGH-UHFFFAOYSA-N 0.000 description 1
QZOCLTJMTFTJNJ-UHFFFAOYSA-N acetic acid;n-[4-[4-amino-1-[4-[(4-hydroxypiperidin-1-yl)methyl]phenyl]pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide Chemical compound CC(O)=O.COC1=CC(C=2C3=C(N)N=CN=C3N(C=3C=CC(CN4CCC(O)CC4)=CC=3)N=2)=CC=C1NC(=O)C1=CC=C(C(F)(F)F)C=C1F QZOCLTJMTFTJNJ-UHFFFAOYSA-N 0.000 description 1
239000012190 activator Substances 0.000 description 1
239000012042 active reagent Substances 0.000 description 1
206010069351 acute lung injury Diseases 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
210000000577 adipose tissue Anatomy 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
239000004479 aerosol dispenser Substances 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
206010064930 age-related macular degeneration Diseases 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
230000009285 allergic inflammation Effects 0.000 description 1
230000000735 allogeneic effect Effects 0.000 description 1
OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
230000036783 anaphylactic response Effects 0.000 description 1
208000003455 anaphylaxis Diseases 0.000 description 1
239000002870 angiogenesis inducing agent Substances 0.000 description 1
238000002583 angiography Methods 0.000 description 1
230000003501 anti-edematous effect Effects 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000001028 anti-proliverative effect Effects 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
229940125715 antihistaminic agent Drugs 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
229940111121 antirheumatic drug quinolines Drugs 0.000 description 1
230000001640 apoptogenic effect Effects 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
239000008135 aqueous vehicle Substances 0.000 description 1
150000001483 arginine derivatives Chemical class 0.000 description 1
230000002917 arthritic effect Effects 0.000 description 1
238000011914 asymmetric synthesis Methods 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
125000005605 benzo group Chemical group 0.000 description 1
150000001558 benzoic acid derivatives Chemical class 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
229940000635 beta-alanine Drugs 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
229920000249 biocompatible polymer Polymers 0.000 description 1
230000001851 biosynthetic effect Effects 0.000 description 1
210000002459 blastocyst Anatomy 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
230000024279 bone resorption Effects 0.000 description 1
239000012888 bovine serum Substances 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
208000001969 capillary hemangioma Diseases 0.000 description 1
230000002612 cardiopulmonary effect Effects 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
230000020411 cell activation Effects 0.000 description 1
230000021164 cell adhesion Effects 0.000 description 1
230000034196 cell chemotaxis Effects 0.000 description 1
230000032823 cell division Effects 0.000 description 1
239000013592 cell lysate Substances 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000019522 cellular metabolic process Effects 0.000 description 1
230000005754 cellular signaling Effects 0.000 description 1
229940081734 cellulose acetate phthalate Drugs 0.000 description 1
208000026106 cerebrovascular disease Diseases 0.000 description 1
210000003679 cervix uteri Anatomy 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
OGEBRHQLRGFBNV-RZDIXWSQSA-N chembl2036808 Chemical group C12=NC(NCCCC)=NC=C2C(C=2C=CC(F)=CC=2)=NN1C[C@H]1CC[C@H](N)CC1 OGEBRHQLRGFBNV-RZDIXWSQSA-N 0.000 description 1
150000005829 chemical entities Chemical class 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
230000035605 chemotaxis Effects 0.000 description 1
NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
238000003501 co-culture Methods 0.000 description 1
230000003081 coactivator Effects 0.000 description 1
238000000576 coating method Methods 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
230000001010 compromised effect Effects 0.000 description 1
235000009508 confectionery Nutrition 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
239000000470 constituent Substances 0.000 description 1
229940124558 contraceptive agent Drugs 0.000 description 1
239000003433 contraceptive agent Substances 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
229940111134 coxibs Drugs 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
239000003260 cyclooxygenase 1 inhibitor Substances 0.000 description 1
239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
108010004073 cysteinylcysteine Proteins 0.000 description 1
201000003146 cystitis Diseases 0.000 description 1
230000016396 cytokine production Effects 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
239000002254 cytotoxic agent Substances 0.000 description 1
231100000599 cytotoxic agent Toxicity 0.000 description 1
238000011393 cytotoxic chemotherapy Methods 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000009849 deactivation Effects 0.000 description 1
230000034994 death Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
229960003964 deoxycholic acid Drugs 0.000 description 1
238000010511 deprotection reaction Methods 0.000 description 1
230000001687 destabilization Effects 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
125000004663 dialkyl amino group Chemical group 0.000 description 1
125000003963 dichloro group Chemical group Cl* 0.000 description 1
235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
229960001760 dimethyl sulfoxide Drugs 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
230000007783 downstream signaling Effects 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
238000007876 drug discovery Methods 0.000 description 1
239000000428 dust Substances 0.000 description 1
239000000975 dye Substances 0.000 description 1
230000002497 edematous effect Effects 0.000 description 1
239000012636 effector Substances 0.000 description 1
230000013020 embryo development Effects 0.000 description 1
210000002257 embryonic structure Anatomy 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
239000007920 enema Substances 0.000 description 1
229940079360 enema for constipation Drugs 0.000 description 1
238000001952 enzyme assay Methods 0.000 description 1
230000032050 esterification Effects 0.000 description 1
238000005886 esterification reaction Methods 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
229960005309 estradiol Drugs 0.000 description 1
229930182833 estradiol Natural products 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000284 extract Substances 0.000 description 1
210000003414 extremity Anatomy 0.000 description 1
208000030533 eye disease Diseases 0.000 description 1
239000003889 eye drop Substances 0.000 description 1
229940012356 eye drops Drugs 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
230000035558 fertility Effects 0.000 description 1
239000002871 fertility agent Substances 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
229950003499 fibrin Drugs 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
230000003176 fibrotic effect Effects 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000011888 foil Substances 0.000 description 1
239000012634 fragment Substances 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
238000007306 functionalization reaction Methods 0.000 description 1
HYBBIBNJHNGZAN-UHFFFAOYSA-N furfural Chemical compound O=CC1=CC=CO1 HYBBIBNJHNGZAN-UHFFFAOYSA-N 0.000 description 1
230000004927 fusion Effects 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
208000005017 glioblastoma Diseases 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
239000002622 gonadotropin Substances 0.000 description 1
238000000227 grinding Methods 0.000 description 1
229940093915 gynecological organic acid Drugs 0.000 description 1
201000011066 hemangioma Diseases 0.000 description 1
201000005787 hematologic cancer Diseases 0.000 description 1
208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
210000003958 hematopoietic stem cell Anatomy 0.000 description 1
208000018706 hematopoietic system disease Diseases 0.000 description 1
108060003552 hemocyanin Proteins 0.000 description 1
238000011102 hetero oligomerization reaction Methods 0.000 description 1
125000004475 heteroaralkyl group Chemical group 0.000 description 1
125000006517 heterocyclyl carbonyl group Chemical group 0.000 description 1
231100000086 high toxicity Toxicity 0.000 description 1
229960002885 histidine Drugs 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
102000055590 human KDR Human genes 0.000 description 1
235000003642 hunger Nutrition 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
150000004678 hydrides Chemical class 0.000 description 1
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
229910000041 hydrogen chloride Inorganic materials 0.000 description 1
229920001600 hydrophobic polymer Polymers 0.000 description 1
125000005181 hydroxyalkylaminoalkyl group Chemical group 0.000 description 1
229960002591 hydroxyproline Drugs 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
230000000148 hypercalcaemia Effects 0.000 description 1
208000030915 hypercalcemia disease Diseases 0.000 description 1
230000000521 hyperimmunizing effect Effects 0.000 description 1
239000005457 ice water Substances 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
150000005232 imidazopyridines Chemical class 0.000 description 1
230000002519 immonomodulatory effect Effects 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000036737 immune function Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
229940125721 immunosuppressive agent Drugs 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
239000007943 implant Substances 0.000 description 1
238000002513 implantation Methods 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
238000010874 in vitro model Methods 0.000 description 1
230000000415 inactivating effect Effects 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
150000002475 indoles Chemical class 0.000 description 1
210000004969 inflammatory cell Anatomy 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
230000004073 interleukin-2 production Effects 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
208000023589 ischemic disease Diseases 0.000 description 1
125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
210000001117 keloid Anatomy 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
230000003902 lesion Effects 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
229940057995 liquid paraffin Drugs 0.000 description 1
DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
230000001926 lymphatic effect Effects 0.000 description 1
210000005073 lymphatic endothelial cell Anatomy 0.000 description 1
210000001365 lymphatic vessel Anatomy 0.000 description 1
239000008176 lyophilized powder Substances 0.000 description 1
239000012139 lysis buffer Substances 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000003550 marker Substances 0.000 description 1
230000035800 maturation Effects 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
230000031864 metaphase Effects 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
VUJAYVQXGDNUAY-UQTORGHUSA-N methyl (2s)-2-[[4-[4-amino-3-[4-[[2-fluoro-4-(trifluoromethyl)benzoyl]amino]-3-methoxyphenyl]pyrazolo[3,4-d]pyrimidin-1-yl]phenyl]methylamino]-3-(4h-imidazol-4-yl)propanoate Chemical compound C([C@@H](C(=O)OC)NCC=1C=CC(=CC=1)N1C2=NC=NC(N)=C2C(C=2C=C(OC)C(NC(=O)C=3C(=CC(=CC=3)C(F)(F)F)F)=CC=2)=N1)C1C=NC=N1 VUJAYVQXGDNUAY-UQTORGHUSA-N 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
210000004088 microvessel Anatomy 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000003801 milling Methods 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
239000011707 mineral Substances 0.000 description 1
229960004857 mitomycin Drugs 0.000 description 1
230000011278 mitosis Effects 0.000 description 1
230000000394 mitotic effect Effects 0.000 description 1
125000002950 monocyclic group Chemical group 0.000 description 1
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 1
230000036473 myasthenia Effects 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
230000002107 myocardial effect Effects 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
NYIODHFKZFKMSU-UHFFFAOYSA-N n,n-bis(methylamino)ethanamine Chemical compound CCN(NC)NC NYIODHFKZFKMSU-UHFFFAOYSA-N 0.000 description 1
MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
QUFLYHVAZIWSLF-UHFFFAOYSA-N n-[4-[4-amino-1-(2-imidazol-1-ylethyl)pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methylindole-2-carboxamide Chemical compound C=1C=C(NC(=O)C=2N(C3=CC=CC=C3C=2)C)C(OC)=CC=1C(C1=C(N)N=CN=C11)=NN1CCN1C=CN=C1 QUFLYHVAZIWSLF-UHFFFAOYSA-N 0.000 description 1
AZUVGEIOZJBHCP-UHFFFAOYSA-N n-[4-[4-amino-1-(4-oxocyclohexyl)pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide Chemical compound COC1=CC(C=2C3=C(N)N=CN=C3N(C3CCC(=O)CC3)N=2)=CC=C1NC(=O)C1=CC=C(C(F)(F)F)C=C1F AZUVGEIOZJBHCP-UHFFFAOYSA-N 0.000 description 1
FKCKZGCZKWLAEL-UHFFFAOYSA-N n-[4-[4-amino-1-[4-[(3-methoxypropylamino)methyl]phenyl]pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide Chemical compound C1=CC(CNCCCOC)=CC=C1N1C2=NC=NC(N)=C2C(C=2C=C(OC)C(NC(=O)C=3C(=CC(=CC=3)C(F)(F)F)F)=CC=2)=N1 FKCKZGCZKWLAEL-UHFFFAOYSA-N 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
230000027405 negative regulation of phosphorylation Effects 0.000 description 1
230000001272 neurogenic effect Effects 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
231100000956 nontoxicity Toxicity 0.000 description 1
238000010899 nucleation Methods 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
239000012044 organic layer Substances 0.000 description 1
239000003791 organic solvent mixture Substances 0.000 description 1
230000008520 organization Effects 0.000 description 1
229960003104 ornithine Drugs 0.000 description 1
210000000963 osteoblast Anatomy 0.000 description 1
208000008798 osteoma Diseases 0.000 description 1
201000008968 osteosarcoma Diseases 0.000 description 1
210000003101 oviduct Anatomy 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
201000002528 pancreatic cancer Diseases 0.000 description 1
208000008443 pancreatic carcinoma Diseases 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
230000003076 paracrine Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000000149 penetrating effect Effects 0.000 description 1
230000035515 penetration Effects 0.000 description 1
GJVFBWCTGUSGDD-UHFFFAOYSA-L pentamethonium bromide Chemical compound [Br-].[Br-].C[N+](C)(C)CCCCC[N+](C)(C)C GJVFBWCTGUSGDD-UHFFFAOYSA-L 0.000 description 1
229950000964 pepstatin Drugs 0.000 description 1
108010091212 pepstatin Proteins 0.000 description 1
FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
150000002978 peroxides Chemical class 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
239000002957 persistent organic pollutant Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
210000004214 philadelphia chromosome Anatomy 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 description 1
239000000049 pigment Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
HXEACLLIILLPRG-UHFFFAOYSA-N pipecolic acid Chemical compound OC(=O)C1CCCCN1 HXEACLLIILLPRG-UHFFFAOYSA-N 0.000 description 1
PRAYXGYYVXRDDW-UHFFFAOYSA-N piperidin-2-ylmethanol Chemical compound OCC1CCCCN1 PRAYXGYYVXRDDW-UHFFFAOYSA-N 0.000 description 1
VUNPWIPIOOMCPT-UHFFFAOYSA-N piperidin-3-ylmethanol Chemical compound OCC1CCCNC1 VUNPWIPIOOMCPT-UHFFFAOYSA-N 0.000 description 1
210000002826 placenta Anatomy 0.000 description 1
230000028742 placenta development Effects 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
201000003437 pleural cancer Diseases 0.000 description 1
239000003495 polar organic solvent Substances 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
125000003367 polycyclic group Chemical group 0.000 description 1
229940068886 polyethylene glycol 300 Drugs 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010988 polyoxyethylene sorbitan tristearate Nutrition 0.000 description 1
239000001816 polyoxyethylene sorbitan tristearate Substances 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
150000004804 polysaccharides Chemical class 0.000 description 1
229940099511 polysorbate 65 Drugs 0.000 description 1
230000004481 post-translational protein modification Effects 0.000 description 1
SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 1
159000000001 potassium salts Chemical class 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
229940116317 potato starch Drugs 0.000 description 1
238000002953 preparative HPLC Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
238000003825 pressing Methods 0.000 description 1
210000004986 primary T-cell Anatomy 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
230000000770 proinflammatory effect Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
239000003380 propellant Substances 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
230000029983 protein stabilization Effects 0.000 description 1
230000006337 proteolytic cleavage Effects 0.000 description 1
239000003586 protic polar solvent Substances 0.000 description 1
208000005333 pulmonary edema Diseases 0.000 description 1
150000003230 pyrimidines Chemical class 0.000 description 1
150000004943 pyrrolo[2,3-d]pyrimidines Chemical class 0.000 description 1
238000007348 radical reaction Methods 0.000 description 1
150000003254 radicals Chemical class 0.000 description 1
229920005604 random copolymer Polymers 0.000 description 1
230000007115 recruitment Effects 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
230000006884 regulation of angiogenesis Effects 0.000 description 1
230000022983 regulation of cell cycle Effects 0.000 description 1
230000008439 repair process Effects 0.000 description 1
230000010410 reperfusion Effects 0.000 description 1
230000001850 reproductive effect Effects 0.000 description 1
210000001525 retina Anatomy 0.000 description 1
229940100486 rice starch Drugs 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
230000007017 scission Effects 0.000 description 1
238000007790 scraping Methods 0.000 description 1
238000012216 screening Methods 0.000 description 1
238000007789 sealing Methods 0.000 description 1
230000028327 secretion Effects 0.000 description 1
150000003346 selenoethers Chemical class 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
208000007056 sickle cell anemia Diseases 0.000 description 1
210000000329 smooth muscle myocyte Anatomy 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
239000007901 soft capsule Substances 0.000 description 1
239000012439 solid excipient Substances 0.000 description 1
239000012265 solid product Substances 0.000 description 1
238000009331 sowing Methods 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
239000007858 starting material Substances 0.000 description 1
230000037351 starvation Effects 0.000 description 1
210000000130 stem cell Anatomy 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000012089 stop solution Substances 0.000 description 1
125000003011 styrenyl group Chemical class [H]\C(*)=C(/[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000013589 supplement Substances 0.000 description 1
230000008093 supporting effect Effects 0.000 description 1
239000002511 suppository base Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
201000000596 systemic lupus erythematosus Diseases 0.000 description 1
230000008685 targeting Effects 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
230000002123 temporal effect Effects 0.000 description 1
208000001608 teratocarcinoma Diseases 0.000 description 1
150000003536 tetrazoles Chemical class 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
231100001274 therapeutic index Toxicity 0.000 description 1
125000004001 thioalkyl group Chemical group 0.000 description 1
229930192474 thiophene Natural products 0.000 description 1
229960004072 thrombin Drugs 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
239000003104 tissue culture media Substances 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
238000010361 transduction Methods 0.000 description 1
230000026683 transduction Effects 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000005945 translocation Effects 0.000 description 1
102000027257 transmembrane receptors Human genes 0.000 description 1
108091008578 transmembrane receptors Proteins 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
150000003852 triazoles Chemical class 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
229940029284 trichlorofluoromethane Drugs 0.000 description 1
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
239000002451 tumor necrosis factor inhibitor Substances 0.000 description 1
238000013414 tumor xenograft model Methods 0.000 description 1
208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
210000003606 umbilical vein Anatomy 0.000 description 1
LSGOVYNHVSXFFJ-UHFFFAOYSA-N vanadate(3-) Chemical compound [O-][V]([O-])([O-])=O LSGOVYNHVSXFFJ-UHFFFAOYSA-N 0.000 description 1
208000019553 vascular disease Diseases 0.000 description 1
230000006711 vascular endothelial growth factor production Effects 0.000 description 1
210000005166 vasculature Anatomy 0.000 description 1
230000000982 vasogenic effect Effects 0.000 description 1
201000009371 venous hemangioma Diseases 0.000 description 1
230000029812 viral genome replication Effects 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
239000011534 wash buffer Substances 0.000 description 1
238000005406 washing Methods 0.000 description 1
238000005303 weighing Methods 0.000 description 1
229940100445 wheat starch Drugs 0.000 description 1
210000000707 wrist Anatomy 0.000 description 1
JPZXHKDZASGCLU-LBPRGKRZSA-N β-(2-naphthyl)-alanine Chemical compound C1=CC=CC2=CC(C[C@H](N)C(O)=O)=CC=C21 JPZXHKDZASGCLU-LBPRGKRZSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Pulmonology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

BG108286A 2001-04-27 2003-10-23 Използване на азитромицин за получаване на фармацевтично средство за лечение на възпалителни неинфекциозни заболявания BG108286A (bg)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
HR20010301A HRP20010301A2 (en)	2001-04-27	2001-04-27	New therapeutic indication for azithromycin in the treatment of non-infective inflammatory diseases
PCT/EP2002/003984 WO2002087596A2 (en)	2001-04-27	2002-04-10	Use of azithromycin for the manufacture of a medicament for treatment of non-infective inflammatory diseases

Publications (1)

Publication Number	Publication Date
BG108286A true BG108286A (bg)	2004-09-30

Family

ID=10947306

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG108286A BG108286A (bg)	2001-04-27	2003-10-23	Използване на азитромицин за получаване на фармацевтично средство за лечение на възпалителни неинфекциозни заболявания

Country Status (19)

Country	Link
US (1)	US20050054587A1 (cs)
EP (1)	EP1392327A2 (cs)
JP (1)	JP2004531539A (cs)
CN (1)	CN1582158A (cs)
AR (1)	AR034223A1 (cs)
BG (1)	BG108286A (cs)
BR (1)	BR0209276A (cs)
CA (1)	CA2443381A1 (cs)
CZ (1)	CZ20032932A3 (cs)
EA (1)	EA200301187A1 (cs)
HR (1)	HRP20010301A2 (cs)
HU (1)	HUP0303988A2 (cs)
IL (1)	IL158236A0 (cs)
MX (1)	MXPA03009849A (cs)
PL (1)	PL364086A1 (cs)
SK (1)	SK13352003A3 (cs)
WO (1)	WO2002087596A2 (cs)
YU (1)	YU84503A (cs)
ZA (1)	ZA200308933B (cs)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HRP20020231A2 (en)	2002-03-18	2003-12-31	Pliva D D	ISOSTRUCTURAL PSEUDOPOLYMORPHS OF 9-DEOXO-9a-AZA-9a-METHYL-9a-HOMOERYTHROMYCIN A
HRP20020614A2 (en)	2002-07-22	2004-06-30	PLIVA-ISTRAŽIVAČKI INSTITUT d.o.o.	Rhombic pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin a
GB0315671D0 (en)	2003-07-04	2003-08-13	Chelsea And Westminster Nhs Tr	Improvements in or relating to organic compounds
JP2007516951A (ja) *	2003-12-30	2007-06-28	アステラス製薬株式会社	気道閉塞症の治療または予防のためのマクロライドの使用
US7468428B2 (en)	2004-03-17	2008-12-23	App Pharmaceuticals, Llc	Lyophilized azithromycin formulation
WO2006115494A1 (en) *	2005-04-26	2006-11-02	American Pharmaceutical Partners, Inc.	Lyophilized azithromycin formulation
JP3933683B2 (ja)	2004-07-02	2007-06-20	わかもと製薬株式会社	アジスロマイシン含有水性医薬組成物及びその調製方法
WO2006097849A1 (en) *	2005-01-14	2006-09-21	Glaxosmithkline Istrazivacki Centar Zagreb D.O.O.	9a-carbamoyl and thiocarbamoyl azalides with anti-inflammatory activity
US20060293261A1 (en)	2005-06-24	2006-12-28	Taisho Pharmaceutical Co., Ltd.	Clarithromycin or a salt thereof for the treatment or prevention of pulmonary disorders caused by the destruction of pulmonary alveoli
EP2010153A2 (en) *	2006-04-03	2009-01-07	Teva Pharmaceutical Industries Limited	Drug microparticles
RU2455308C2 (ru)	2006-05-01	2012-07-10	Тайсо Фармасьютикал Ко., Лтд.	Макролидные производные
US7704959B2 (en) *	2006-10-03	2010-04-27	Dow Pharmaceutical Sciences	Azithromycin for the treatment of nodular acne
JP2011527709A (ja) *	2008-07-10	2011-11-04	インスパイアーファーマシューティカルズ，インコーポレイティド	眼瞼炎の治療方法
WO2010062787A1 (en)	2008-11-03	2010-06-03	Washington University	Bioluminescence imaging of myeloperoxidase activity in vivo, methods, compositions and apparatuses therefor
EP2393355A4 (en) *	2009-01-23	2012-07-25	Inspire Pharmaceuticals Inc	METHOD FOR TREATING A DRY EYE WITH AZITHROMYCIN
CN102378763A (zh)	2009-01-30	2012-03-14	葛兰素集团有限公司	消炎的大环内酯
WO2011116312A1 (en) *	2010-03-19	2011-09-22	Catabasis Pharmaceuticals, Inc.	Fatty acid macrolide derivatives and their uses
WO2017010382A1 (ja) *	2015-07-14	2017-01-19	国立大学法人大阪大学	筋強直性ジストロフィー治療薬
CN113209084A (zh) *	2021-05-18	2021-08-06	南开大学	化合物cp0119在制备用于治疗炎性肠病的药物中的应用
WO2025235305A1 (en)	2024-05-06	2025-11-13	Baxter International Inc.	Azithromycin premix formulation and product, methods of preparing same, and methods of using same

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
YU43116B (en) *	1979-04-02	1989-04-30	Pliva Pharm & Chem Works	Process for preparing 11-aza-4-o-cladinosyl-6-o-desosaminyl-15-ethyl-7,13,14-trihydroxy-3,5,7,9,12,14-hexamethyl-oxacyclopentadecane-2-one(11-aza-10-deox
SI8110592A8 (en) *	1981-03-06	1996-06-30	Pliva Pharm & Chem Works	Process for preparing of n-methyl-11-aza-10-deoxo-10-dihydroerythromycine a and derivatives thereof
YU45590A (sh) *	1990-03-07	1992-07-20	PLIVA FARMACEVTSKA, KEMIJSKA, PREHRAMBENA I KOZMETIČKA INDUSTRIJA s.p.o.	Novi kompleksi odnosno helati antibiotika s dvovalentnim i/ili trovalentnim metalima i postupci za njihovo dobijanje
SI9011409A (en) *	1990-07-18	1995-10-31	Pliva Pharm & Chem Works	O-methyl azitromycin derivates, methods and intermediates for their preparation and methods for preparation of pharmaceuticals products which comprise them
AU7957994A (en) *	1993-10-01	1995-05-01	Procter & Gamble Company, The	Use of azithromycin for the treatment of adult periodontitis and topical compositions for this use
US5605889A (en) *	1994-04-29	1997-02-25	Pfizer Inc.	Method of administering azithromycin
HUT77530A (hu) *	1994-05-06	1998-05-28	Pfizer Inc.	Azitromicint tartalmazó, szabályozott hatóanyag-felszabadítású dózisformák
GB9723669D0 (en) *	1997-11-07	1998-01-07	Univ Aberdeen	Skin penetration enhancing components
DE19850445A1 (de) *	1998-11-02	2000-05-04	Falk Pharma Gmbh	Arzneimittel zur topischen Behandlung entzündlicher Darmerkrankungen
AU5820400A (en) *	1999-06-29	2001-01-31	Biochemie S.A.	Macrolides
IT1313610B1 (it) *	1999-08-09	2002-09-09	S I F I Societa Ind Farmaceuti	Processo per la preparazione di formulazioni acquose per uso oftalmico
IL141438A0 (en) *	2000-02-23	2002-03-10	Pfizer Prod Inc	Method of increasing the bioavailability and tissue penetration of azithromycin

2001
- 2001-04-27 HR HR20010301A patent/HRP20010301A2/hr not_active Application Discontinuation
2002
- 2002-04-10 SK SK13352003A patent/SK13352003A3/sk not_active Application Discontinuation
- 2002-04-10 CN CNA028089162A patent/CN1582158A/zh active Pending
- 2002-04-10 EA EA200301187A patent/EA200301187A1/ru unknown
- 2002-04-10 YU YU84503A patent/YU84503A/sh unknown
- 2002-04-10 PL PL02364086A patent/PL364086A1/xx not_active Application Discontinuation
- 2002-04-10 MX MXPA03009849A patent/MXPA03009849A/es unknown
- 2002-04-10 US US10/476,377 patent/US20050054587A1/en not_active Abandoned
- 2002-04-10 HU HU0303988A patent/HUP0303988A2/hu unknown
- 2002-04-10 WO PCT/EP2002/003984 patent/WO2002087596A2/en not_active Ceased
- 2002-04-10 JP JP2002584941A patent/JP2004531539A/ja active Pending
- 2002-04-10 CZ CZ20032932A patent/CZ20032932A3/cs unknown
- 2002-04-10 EP EP02737939A patent/EP1392327A2/en not_active Withdrawn
- 2002-04-10 IL IL15823602A patent/IL158236A0/xx unknown
- 2002-04-10 CA CA002443381A patent/CA2443381A1/en not_active Abandoned
- 2002-04-10 BR BR0209276-0A patent/BR0209276A/pt not_active IP Right Cessation
- 2002-04-26 AR ARP020101524A patent/AR034223A1/es unknown
2003
- 2003-10-23 BG BG108286A patent/BG108286A/bg unknown
- 2003-11-17 ZA ZA200308933A patent/ZA200308933B/en unknown

Also Published As

Publication number	Publication date
CA2443381A1 (en)	2002-11-07
YU84503A (sh)	2006-08-17
IL158236A0 (en)	2004-05-12
WO2002087596A2 (en)	2002-11-07
PL364086A1 (en)	2004-12-13
CN1582158A (zh)	2005-02-16
SK13352003A3 (en)	2004-10-05
WO2002087596A3 (en)	2003-01-03
JP2004531539A (ja)	2004-10-14
EA200301187A1 (ru)	2004-04-29
EP1392327A2 (en)	2004-03-03
ZA200308933B (en)	2004-11-17
HRP20010301A2 (en)	2001-12-31
BR0209276A (pt)	2004-06-15
MXPA03009849A (es)	2004-05-24
HUP0303988A2 (hu)	2004-04-28
US20050054587A1 (en)	2005-03-10
AR034223A1 (es)	2004-02-04
CZ20032932A3 (cs)	2004-08-18

Publication	Publication Date	Title
US7332497B2 (en)	2008-02-19	Pyrazolopyrimidines as therapeutic agents
JP4707167B2 (ja)	2011-06-22	キナーゼ阻害剤
US6921763B2 (en)	2005-07-26	Pyrazolopyrimidines as therapeutic agents
US7829570B2 (en)	2010-11-09	Substituted 4-amino isoxazolo[5,4-d]pyrimidines as kinase inhibitors
EP1114052B1 (en)	2005-11-16	4-aminopyrrolopyrimidines as kinase inhibitors
BG108286A (bg)	2004-09-30	Използване на азитромицин за получаване на фармацевтично средство за лечение на възпалителни неинфекциозни заболявания
AU7491400A (en)	2001-04-17	Kinase inhibitors as therapeutic agents
US7071199B1 (en)	2006-07-04	Kinase inhibitors as therapeutic agents
JP2003509428A (ja)	2003-03-11	治療薬としてのピラゾロピリミジン
SK3842001A3 (en)	2002-04-04	Pyrrolopyrimidines as protein kinase inhibitors (revised)
JP2007520559A (ja)	2007-07-26	治療薬としてのアミノベンゾオキサゾール類
AU2002258590A1 (en)	2002-10-08	Pyrazolopyrimidines as Therapeutic Agents
AU2002316030A1 (en)	2002-10-21	Pyrazolopyrimidines as therapeutic agents